Cyclooxygenase-2 expression in Barrett's esophagus.

Area of Science:

• Gastroenterology
• Oncology
• Molecular Biology

Background:

• Barrett's epithelium is a premalignant condition for esophageal adenocarcinoma.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) show potential in reducing cancer risk.
• Previous research on cyclooxygenase-2 (COX-2) in Barrett's mucosa yielded conflicting results.

Purpose of the Study:

• To investigate the protein expression of COX-2 in Barrett's esophagus compared to normal esophageal mucosa.
• To determine if COX-2 expression correlates with the presence or absence of dysplasia in Barrett's esophagus.

Main Methods:

• Pinch mucosal biopsies were obtained from 17 patients with Barrett's esophagus, sampling both affected and adjacent normal tissues.
• Immunohistochemistry was used to detect and compare COX-2 and COX-1 protein expression levels.
• Patients were categorized based on the presence or absence of low-grade dysplasia.

Main Results:

• COX-2 protein was undetectable in normal esophageal mucosa.
• COX-1 protein expression remained consistent between normal and Barrett's epithelium.
• Increased COX-2 protein was observed in 41% of Barrett's epithelium samples.
• The elevated COX-2 levels did not significantly differ between samples with or without dysplasia.

Conclusions:

• COX-2 protein is upregulated in a significant subset of patients with Barrett's epithelium.
• The observed increase in COX-2 protein appears to be an early event in the pathogenesis of Barrett's esophagus.
• Further research into COX-2's role may inform therapeutic strategies for esophageal adenocarcinoma prevention.